Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study Confirms Poor Prognosis Post-HSCT in DLBCL

Key clinical point: Despite treatment with active salvage therapy, the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) who relapse following hematopoietic stem cell transplant (HSCT) is poor.

Major finding: The median time to relapse after autologous HSCT was 7 months, with a 3-year overall survival rate of 27% and overall response rate of 46% post-salvage therapy.

Study details: A retrospective analysis of 256 patients with DLBCL who relapsed following auto-HSCT and received active salvage therapy. Data came from the European Society for Blood and Marrow Transplantation.

Disclosures: No funding sources were reported. The authors reported having no conflicts of interest.

Citation:

González-Barca E et al. Bone Marrow Transplant. 2019 Sep 20. doi: 10.1038/s41409-019-0650-x.